NRX Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit)
NRX Pharmaceuticals, Inc. (NRXP) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-31.
Discontinued › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2023-03-31
- NRX Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
- NRX Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2021 was $0.00.
- NRX Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2020 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-31 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-31 |
| 2020-12-31 | $0.00 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |